Bessemer Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.23M | Buy |
22,362
+73
| +0.3% | +$12.8K | 0.01% | 539 |
|
|
2025
Q4 | $3.79M | Buy |
22,289
+19,088
| +596% | +$2.93M | 0.01% | 508 |
|
|
2025
Q3 | $422K | Buy |
3,201
+3
| +0.1% | +$360 | ﹤0.01% | 915 |
|
|
2025
Q2 | $339K | Sell |
3,198
-5,384
| -63% | -$585K | ﹤0.01% | 955 |
|
|
2025
Q1 | $1.06M | Sell |
8,582
-18,350
| -68% | -$2.39M | ﹤0.01% | 677 |
|
|
2024
Q4 | $3.32M | Buy |
26,932
+92
| +0.3% | +$10.8K | 0.01% | 530 |
|
|
2024
Q3 | $2.99M | Buy |
26,840
+26,739
| +26,474% | +$2.93M | ﹤0.01% | 588 |
|
|
2024
Q2 | $11K | Buy |
101
+41
| +68% | +$4.51K | ﹤0.01% | 1495 |
|
|
2024
Q1 | $8K | Sell |
60
-3,910
| -98% | -$479K | ﹤0.01% | 1597 |
|
|
2023
Q4 | $488K | Sell |
3,970
-399
| -9% | -$49.8K | ﹤0.01% | 830 |
|
|
2023
Q3 | $565K | Sell |
4,369
-36
| -0.8% | -$4.8K | ﹤0.01% | 766 |
|
|
2023
Q2 | $545K | Buy |
4,405
+35
| +0.8% | +$4.71K | ﹤0.01% | 781 |
|
|
2023
Q1 | $639K | Buy |
4,370
+1
| +0% | +$148 | ﹤0.01% | 682 |
|
|
2022
Q4 | $696K | Buy |
4,369
+54
| +1% | +$7.91K | ﹤0.01% | 655 |
|
|
2022
Q3 | $575K | Buy |
4,315
+233
| +6% | +$35.4K | ﹤0.01% | 684 |
|
|
2022
Q2 | $637K | Sell |
4,082
-202
| -5% | -$31.1K | ﹤0.01% | 652 |
|
|
2022
Q1 | $667K | Buy |
4,284
+1,251
| +41% | +$182K | ﹤0.01% | 564 |
|
|
2021
Q4 | $386K | Buy |
3,033
+947
| +45% | +$124K | ﹤0.01% | 699 |
|
|
2021
Q3 | $272K | Buy |
2,086
+25
| +1% | +$3.78K | ﹤0.01% | 708 |
|
|
2021
Q2 | $366K | Sell |
2,061
-341
| -14% | -$59.1K | ﹤0.01% | 647 |
|
|
2021
Q1 | $395K | Buy |
2,402
+490
| +26% | +$80.6K | ﹤0.01% | 599 |
|
|
2020
Q4 | $316K | Buy |
1,912
+159
| +9% | +$23.7K | ﹤0.01% | 631 |
|
|
2020
Q3 | $250K | Buy |
+1,753
| New | +$217K | ﹤0.01% | 674 |
|
|
2019
Q2 | – | Sell |
-7
| Closed | -$1K | – | 1726 |
|
|
2019
Q1 | $1K | Sell |
7
-11
| -61% | -$1.44K | ﹤0.01% | 1721 |
|
|
2018
Q4 | $2K | Hold |
18
| – | – | ﹤0.01% | 1874 |
|
|
2018
Q3 | $3K | Buy |
+18
| New | +$3.1K | ﹤0.01% | 1737 |
|
|
2018
Q1 | – | Sell |
-81
| Closed | -$11K | – | 1739 |
|
|
2017
Q4 | $11K | Hold |
81
| – | – | ﹤0.01% | 1488 |
|
|
2017
Q3 | $12K | Hold |
81
| – | – | ﹤0.01% | 1577 |
|
|
2017
Q2 | $13K | Sell |
81
-81
| -50% | -$12.4K | ﹤0.01% | 1551 |
|
|
2017
Q1 | $24K | Sell |
162
-158
| -49% | -$20.6K | ﹤0.01% | 1425 |
|
|
2016
Q4 | $35K | Buy |
320
+144
| +82% | +$16K | ﹤0.01% | 1415 |
|
|
2016
Q3 | $21K | Buy |
176
+14
| +9% | +$1.89K | ﹤0.01% | 1359 |
|
|
2016
Q2 | $23K | Hold |
162
| – | – | ﹤0.01% | 973 |
|
|
2016
Q1 | $21K | Hold |
162
| – | – | ﹤0.01% | 1055 |
|
|
2015
Q4 | $23K | Sell |
162
-19
| -10% | -$2.63K | ﹤0.01% | 1105 |
|
|
2015
Q3 | $24K | Sell |
181
-62
| -26% | -$10.7K | ﹤0.01% | 1086 |
|
|
2015
Q2 | $43K | Buy |
243
+81
| +50% | +$14.5K | ﹤0.01% | 996 |
|
|
2015
Q1 | $28K | Sell |
162
-87
| -35% | -$14.9K | ﹤0.01% | 1080 |
|
|
2014
Q4 | $40K | Buy |
+249
| New | +$41.3K | ﹤0.01% | 980 |
|
|
2014
Q3 | – | Sell |
-137
| Closed | -$20K | – | 1317 |
|
|
2014
Q2 | $20K | Buy |
+137
| New | +$19K | ﹤0.01% | 1013 |
|
Other funds holding JAZZ
VPM
VCM
EC
Bessemer Group's JAZZ Position: Q1 2026 in Review
Bessemer Group increased its Jazz Pharmaceuticals (JAZZ) stake by 0.33% in Q1 2026, buying an estimated $12.8K and bringing the position to 22,362 shares worth $4.23M. The position accounts for 0.01% of the portfolio, ranked #539.
Bessemer Group first reported a position in JAZZ in Q2 2014 and has held it in 40 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Bessemer Group held 22,362 shares of Jazz Pharmaceuticals worth $4.23M as of Q1 2026.
- Bessemer Group bought 73 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12.8K.
- Jazz Pharmaceuticals made up 0.01% of Bessemer Group's portfolio in Q1 2026, its #539 holding.
- Bessemer Group first reported a position in Jazz Pharmaceuticals in Q2 2014 and has held it in 40 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.